58.76 0.00 (0.00%)
After hours: 4:55PM EST
|Bid||52.00 x 1100|
|Ask||60.00 x 800|
|Day's Range||57.25 - 58.79|
|52 Week Range||39.07 - 60.92|
|Beta (3Y Monthly)||1.94|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||55.79|
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CARLSBAD, Calif., Feb. 13, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) announced today that it will host a live webcast on Wednesday, February 27th at 11:30 a.m. Eastern Time to discuss its 2018 financial results and report on pipeline and business progress. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, proprietary antisense technology platform with the potential to treat diseases where no other therapeutic approaches have proven effective.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Stan Crooke became the CEO of IonisRead More...
Ionis Pharmaceuticals Inc NASDAQ/NGS:IONSView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for IONS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding IONS totaled $2.06 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Ionis Pharmaceuticals Inc (NASDAQ: IONS )'s partner Biogen Inc (NASDAQ: BIIB ) reported fourth-quarter results Wednesday before the market open, revealing that sales of the spinal muscular atrophy treatment ...
CARLSBAD, Calif., Jan. 28, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in antisense therapeutics, today announced that its partner Roche, also known as Genentech in the United States, has enrolled the first patient in a pivotal study of RG6042 (IONIS-HTTRx) for people living with symptoms of Huntington's disease (HD), a hereditary neurodegenerative disorder for which there is currently no approved disease-modifying treatment. RG6042 is the first therapy in pivotal trials designed to target the underlying cause of HD by reducing production of the toxic mutant huntingtin protein (mHTT). Ionis has earned a $35 million milestone payment for the initiation of the study.
Shares of Ionis have climbed 6.3% this year. The biotech is on track to enter four drugs into pivotal clinical studies this year, an analyst said in a bullish note on Ionis.
Ironwood (IRWD) begins a phase I study on CNS-penetrant soluble guanylate cyclase stimulator, IW-6463, for treating severe CNS disorders.
FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.
Alnylam dipped Monday after the FDA agreed to review an amyloidosis treatment from Pfizer in just six months. Pfizer's drug would treat patients with abnormal protein building in the heart.
The Food and Drug Administration approved 59 new drugs in 2018 — hitting at least a four-year record — though fewer biologic drugs passed muster. There were also 17 biologic drugs approved.
CARLSBAD, Calif., Jan. 2, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in antisense therapeutics, today announced that Management will present a Company overview at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 4:00 p.m. PT in San Francisco, CA. A live audio webcast of the presentation will be available on the Investors & Media section of the Company's website, www.ionispharma.com. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, proprietary antisense technology platform with the potential to treat diseases where no other therapeutic approaches have proven effective.
Ionis Pharmaceuticals (IONS) is my top pick as a conservative biotech recommendation in 2019; the company represents a unique blend with an exciting and broad pipeline of drug development candidates balanced by revenue generation from approved drugs, observes John McCamant, editor of The Medical Technology Stock Letter.
In the first nine months of 2018, Spectrum Pharmaceuticals (SPPI) reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively—compared to -$62.7 million and -$0.78 in the same period the previous year.
An experimental gene therapy from Novartis, called Zolgensma, is more cost effective than Biogen and Ionis Pharmaceuticals' treatment for a muscle-wasting disease, experts said this week.
Ionis Pharmaceuticals Inc. said late Thursday that Brett Monia will succeed Stanley Crooke as chief executive in a year. The drug development company said Monia, who is the current chief operating officer, will become CEO in January 2020, and Crooke will become executive chairman of Ionis's board. Shares of Ionis, which were flat after hours, had closed down 2.1% at $49.78 in regular trading Thursday.